1-9 of 9
Huafeng Zhou
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Relationship of JAK2 V617F Allelic Burden (AB) to Demographics, Disease Characteristics, and Response to Therapy in Persist-1, a Randomized Phase III Study of Pacritinib (PAC) Versus Best Available Therapy (BAT) in Patients (pts) with Primary and Secondary Myelofibrosis (MF)

Alessandro M. Vannucchi, Adam Mead, Miklos Egyed, Anita Szoke, Aleksandr Suvorov, Andrew Perkins, Jiri Mayer, Peter Ganly, Harry C. Schouten, Patrizia Tosi, Charles Michael Farber, Pierre Zachee, Jean-Jacques Kiladjian, Jyoti Nangalia, James P. Dean, Huafeng Zhou, Jack W. Singer, Ruben A. Mesa, Claire N. Harrison
Journal: Blood
Blood (2016) 128 (22): 3131.
https://doi.org/10.1182/blood.V128.22.3131.3131
Published: 2016
Journal Articles

Clinical Pharmacology Profile of Pacritinib (PAC), a Novel JAK2/FLT3 Inhibitor

Suliman Al-Fayoumi, Mary S. Campbell, Sherri Amberg, Huafeng Zhou, Lindsey Millard, James P. Dean
Journal: Blood
Blood (2015) 126 (23): 5178.
https://doi.org/10.1182/blood.V126.23.5178.5178
Published: 2015
Journal Articles

Evaluation Of The Effect Of Idelalisib On The QT/QTc Interval In Healthy Subjects

Feng Jin, PhD, Michelle Robeson, ND, Huafeng Zhou, PhD, Andie Nichols, Srini Ramanathan, PhD
Journal: Blood
Blood (2013) 122 (21): 5573.
https://doi.org/10.1182/blood.V122.21.5573.5573
Published: 2013
Journal Articles

Evaluation Of Drug Interaction Profile Of Idelalisib and Its Major Circulating Metabolite, GS-563117, In Healthy Subjects

Feng Jin, PhD, Michelle Robeson, ND, Huafeng Zhou, PhD, Candra Moyer, Sibylle Wilbert, PhD, Bernard Murray, PhD, Srini Ramanathan, PhD
Journal: Blood
Blood (2013) 122 (21): 5574.
https://doi.org/10.1182/blood.V122.21.5574.5574
Published: 2013
Journal Articles

Pharmacokinetics and Safety Of Idelalisib, a Novel PI3Kδ Inhibitor, In Japanese and Caucasian Subjects

Feng Jin, PhD, Michelle Robeson, ND, Huafeng Zhou, PhD, Candra Moyer, Srini Ramanathan, PhD
Journal: Blood
Blood (2013) 122 (21): 5575.
https://doi.org/10.1182/blood.V122.21.5575.5575
Published: 2013
Journal Articles

Exposure-Response Of Idelalisib, a Novel PI3Kδ Inhibitor, Administered As Monotherapy In The Treatment Of Hematologic Malignancies

Feng Jin, PhD, Huafeng Zhou, PhD, Lorna Fang, Xiaoming Li, PhD, Terry Newcomb, MD, Roger Dansey, MD, Srini Ramanathan, PhD
Journal: Blood
Blood (2013) 122 (21): 5054.
https://doi.org/10.1182/blood.V122.21.5054.5054
Published: 2013
Journal Articles

Pharmacokinetics, Metabolism and Excretion Of Idelalisib

Feng Jin, PhD, Michelle Robeson, ND, Huafeng Zhou, PhD, Ellen Kwan, Srini Ramanathan, PhD
Journal: Blood
Blood (2013) 122 (21): 5570.
https://doi.org/10.1182/blood.V122.21.5570.5570
Published: 2013
Journal Articles

The Pharmacokinetics and Safety Of Idelalisib In Subjects With Moderate Or Severe Hepatic Impairment

Feng Jin, PhD, Michelle Robeson, ND, Huafeng Zhou, PhD, Grace Hisoire, Srini Ramanathan, PhD
Journal: Blood
Blood (2013) 122 (21): 5571.
https://doi.org/10.1182/blood.V122.21.5571.5571
Published: 2013
Journal Articles

The Pharmacokinetics and Safety Of Idelalisib In Subjects With Severe Renal Impairment

Feng Jin, PhD, Michelle Robeson, ND, Huafeng Zhou, PhD, Grace Hisoire, Srini Ramanathan, PhD
Journal: Blood
Blood (2013) 122 (21): 5572.
https://doi.org/10.1182/blood.V122.21.5572.5572
Published: 2013